Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study

Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study

Abstract Background Current evidence about the cardiovascular safety of glucagon-like peptide-1 receptor agonist (GLP-1ra) possesses limited generalizability to real-world patients with type 2 diabetes (T2D) in usual practice. This study aimed to investigate the comparative cardiovascular safety of...

Full description

Bibliographic Details
Main Authors:	Chun-Ting Yang, Chen-Yi Yang, Huang-Tz Ou, Shihchen Kuo
Format:	Article
Language:	English
Published:	BMC 2020-06-01
Series:	Cardiovascular Diabetology
Subjects:	GLP-1 receptor agonist Cardiovascular safety DPP-4 inhibitor Sulfonylurea Insulin
Online Access:	http://link.springer.com/article/10.1186/s12933-020-01053-0

Similar Items

Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
by: Mariusz Dąbrowski
Published: (2021-02-01)

Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review
by: Chen-Yi Yang, et al.
Published: (2021-01-01)

Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort study
by: Zi-Yang Peng, et al.
Published: (2023-10-01)

Comparison of Glucose Lowering Efficacy of Human GLP-1 Agonist in Taiwan Type 2 Diabetes Patients after Switching from DPP-4 Inhibitor Use or Non-Use
by: Chia-Jen Tsai, et al.
Published: (2022-11-01)

Pharmacogenetics of Type 2 Diabetes—Progress and Prospects
by: Yulia A. Nasykhova, et al.
Published: (2020-09-01)

Comparative cardiovascular effects of GLP‐1 agonists using real‐world data
by: Amisha Wallia, et al.
Published: (2023-05-01)

The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A Danish nationwide cohort study
by: Zheer Kejlberg Al-Mashhadi, et al.
Published: (2022-10-01)

Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis
by: Chengcong Chen, et al.
Published: (2019-12-01)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
by: Xin Zhao, et al.
Published: (2021-08-01)

Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus
by: Yury Ivanovich Suntsov
Published: (2012-03-01)

Effect of glucagon-like peptide-1 (GLP-1) agonists on the example of semaglutide on the cardiovascular system and their role in the treatment of obesity.
by: Kamil Pondel, et al.
Published: (2022-08-01)

Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
by: Sara Piccini, et al.
Published: (2023-03-01)

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
by: Dario Giugliano, et al.
Published: (2022-03-01)

Inflammation and Incretins
by: Amitabh Hatwal
Published: (2012-01-01)

Effects of Incretin-Related Diabetes Drugs on Bone Formation and Bone Resorption
by: Hideki Kitaura, et al.
Published: (2021-06-01)

Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity
by: Derek Ge, et al.
Published: (2022-12-01)

GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
by: Sydney S. Wilbon, et al.
Published: (2023-12-01)

Risk of Fracture With Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis Combining 177 Randomized Controlled Trials With a Median Follow-Up of 26 weeks
by: Sanbao Chai, et al.
Published: (2022-07-01)

Long-acting agonists of human and rodent GLP-2 receptors for studies of the physiology and pharmacological potential of the GLP-2 system
by: Sarina Gadgaard, et al.
Published: (2023-04-01)

GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease
by: Kallirhoe Kalinderi, et al.
Published: (2024-03-01)

Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists
by: Ghadeer K. Dawwas, et al.
Published: (2018-07-01)

Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes
by: Mohammed A. Al-Sadawi, et al.
Published: (2023-08-01)

Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis
by: Tito Borner, et al.
Published: (2020-06-01)

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
by: Chudleigh RA, et al.
Published: (2020-02-01)

Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
by: Tomislav Bulum
Published: (2022-10-01)

Oat globulin peptides regulate antidiabetic drug targets and glucose transporters in Caco-2 cells
by: Feng Wang, et al.
Published: (2018-03-01)

The Antidiabetic Mechanisms of Polyphenols Related to Increased Glucagon-Like Peptide-1 (GLP1) and Insulin Signaling
by: J. Abraham Domínguez Avila, et al.
Published: (2017-05-01)

Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
by: Mihaela-Simona Popoviciu, et al.
Published: (2023-06-01)

Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
by: Qian Zhou, et al.
Published: (2023-10-01)

Incretins-Based Therapies and Their Cardiovascular Effects: New Game-Changers for the Management of Patients with Diabetes and Cardiovascular Disease
by: Federico Bernardini, et al.
Published: (2023-07-01)

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
by: Jing-Yue Wang, et al.
Published: (2023-02-01)

GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
by: Riccardo Nevola, et al.
Published: (2023-01-01)

GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
by: Andrei C. Sposito, et al.
Published: (2018-12-01)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes
by: Alba Rojano Toimil, et al.
Published: (2021-08-01)

Glucagon-like peptide-1 (GLP-1) mediates the protective effects of dipeptidyl peptidase IV inhibition on pulmonary hypertension
by: Jingjing Wang, et al.
Published: (2019-01-01)

Regimen comprising GLP-1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre-mixed insulin regimen
by: Yi-Hsuan Lin, et al.
Published: (2022-12-01)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
by: Qiao Q, et al.
Published: (2016-06-01)

GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
by: Matthew P. Gilbert, et al.
Published: (2020-04-01)

Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds
by: Wilke T, et al.
Published: (2022-05-01)

The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
by: Haiyang Du, et al.
Published: (2022-11-01)